Who owns Crescent Biopharma Inc?
- Ticker: CBIO
- CUSIP Number: g2545c104
Tip: Access positions for across all investors
Analyze quarterly positions in Crescent Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csvTop investors of Crescent Biopharma stock
Who bought or sold Crescent Biopharma Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| FMR | 4.1M | $74M | 0% | Jun 2026 |
|
| BVF | 2.7M | $50M | 0% | Jun 2026 |
|
| Fairmount Funds Management | 2.7M | $50M | 0% | Jun 2026 |
|
| VR Adviser | 2.1M | $38M | 0% | Jun 2026 |
|
| Logos Global Management | 1.9M | $34M | 294% | Jun 2026 |
|
| Fcpm Iii Services B.v. | 1.7M | $30M | 0% | Jun 2026 |
|
| Balyasny Asset Management | 1.7M | $30M | 10% | Jun 2026 |
|
| Vestal Point Capital | 1.6M | $29M | 9% | Jun 2026 |
|
| Opaleye Management | 1.3M | $24M | 1% | Jun 2026 |
|
| BlackRock | 1.3M | $23M | 999% | Jun 2026 |
|
| Tang Capital Management | 1.2M | $21M | 0% | Jun 2026 |
|
| Vanguard Capital Management | 768k | $14M | -4% | Jun 2026 |
|
| Millennium Management | 404k | $7.3M | 25% | Jun 2026 |
|
| Geode Capital Management | 385k | $6.9M | 269% | Jun 2026 |
|
| Jennison Associates | 379k | $6.8M | 147% | Jun 2026 |
|
| Rtw Investments | 373k | $6.7M | 0% | Jun 2026 |
|
| Remedium Capital Partners | 361k | $6.5M | 100% | Jun 2026 |
|
| T. Rowe Price Associates | 304k | $5.6M | -10% | Mar 2026 |
|
| Ameriprise Financial | 303k | $5.4M | 100% | Jun 2026 |
|
| Point72 Asset Management | 300k | $5.4M | 0% | Jun 2026 |
|
| Marshall Wace | 214k | $3.9M | 7% | Jun 2026 |
|
| Perceptive Advisors | 207k | $3.7M | 0% | Jun 2026 |
|
| Vanguard Portfolio Management | 189k | $3.4M | 100% | Jun 2026 |
|
| Two Sigma Investments | 187k | $3.4M | 61% | Jun 2026 |
|
| Stempoint Capital | 182k | $3.3M | 100% | Jun 2026 |
|
| UBS Group | 175k | $3.2M | 112% | Jun 2026 |
|
| Northern Trust | 139k | $2.5M | 705% | Jun 2026 |
|
| Exome Asset Management | 128k | $2.3M | -17% | Jun 2026 |
|
| Sectoral Asset Management | 121k | $2.2M | 100% | Jun 2026 |
|
| Woodline Partners | 95k | $1.7M | 28% | Jun 2026 |
|
| Vanguard Fiduciary Trust | 75k | $1.4M | 52% | Jun 2026 |
|
| Burkehill Global Management | 74k | $1.3M | 0% | Jun 2026 |
|
| Blackstone Group | 63k | $1.1M | 100% | Jun 2026 |
|
| Silverarc Capital Management | 59k | $1.1M | -55% | Jun 2026 |
|
| Y-Intercept | 51k | $915k | 100% | Jun 2026 |
|
| Charles Schwab Investment Management | 50k | $905k | 100% | Jun 2026 |
|
| Sixth Street Partners Management Company | 50k | $905k | 100% | Jun 2026 |
|
| Nuveen | 48k | $857k | 100% | Jun 2026 |
|
| Bank of New York Mellon | 46k | $824k | 100% | Jun 2026 |
|
| Stonepine Capital Management | 40k | $720k | -53% | Jun 2026 |
|
| State Street Corporation | 39k | $718k | 49% | Mar 2026 |
|
| Bank of America Corporation | 26k | $465k | -12% | Jun 2026 |
|
| Rhumbline Advisers | 26k | $459k | 100% | Jun 2026 |
|
| Moore Capital Management | 25k | $450k | 0% | Jun 2026 |
|
| Squarepoint Ops | 24k | $435k | 100% | Jun 2026 |
|
| American Century Companies | 23k | $411k | 100% | Jun 2026 |
|
| Citigroup | 20k | $371k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 20k | $355k | 100% | Jun 2026 |
|
| Morgan Stanley | 19k | $341k | -32% | Mar 2026 |
|
| ADAR1 Capital Management | 18k | $329k | -64% | Jun 2026 |
|
| Virtus Investment Advisers | 18k | $329k | 100% | Jun 2026 |
|
| Manufacturers Life Insurance Company | 18k | $320k | -29% | Jun 2026 |
|
| Wellington Management Company | 15k | $263k | 100% | Jun 2026 |
|
| MetLife Investment Advisors | 13k | $230k | 100% | Jun 2026 |
|
| Invesco | 12k | $211k | 100% | Jun 2026 |
|
| Persistent Asset Partners | 11k | $197k | 100% | Jun 2026 |
|
| XTX Topco | 11k | $190k | 100% | Jun 2026 |
|
| Mirae Asset Global Etfs Holdings | 9.9k | $178k | 100% | Jun 2026 |
|
| Jpmorgan Chase & Co | 9.0k | $162k | 100% | Jun 2026 |
|
| New York State Common Retirement Fund | 7.6k | $137k | 100% | Jun 2026 |
|
| Police & Firemen's Retirement System of New Jersey | 6.4k | $115k | 100% | Jun 2026 |
|
| Barclays | 4.5k | $80k | -85% | Jun 2026 |
|
| Bnp Paribas Arbitrage, Snc | 3.3k | $60k | -79% | Jun 2026 |
|
| Vanguard Global Advisers | 2.7k | $49k | -22% | Jun 2026 |
|
| Legal & General Group | 2.1k | $38k | 100% | Jun 2026 |
|
| Tower Research Capital | 1.8k | $32k | 100% | Jun 2026 |
|
| Russell Investments | 1.7k | $31k | 100% | Jun 2026 |
|
| Royal Bank of Canada | 681.00 | $12k | 1235% | Jun 2026 |
|
| Us Bancorp | 403.00 | $7.3k | 100% | Jun 2026 |
|
| California State Teachers Retirement System | 297.00 | $5.3k | 100% | Jun 2026 |
|
| Parallel Advisors | 264.00 | $4.8k | 0% | Jun 2026 |
|
| Hanson McClain Advisors | 161.00 | $2.9k | 0% | Jun 2026 |
|
| Sterling Capital Management | 76.00 | $1.4k | 100% | Jun 2026 |
|
| SBI Securities | 68.00 | $1.2k | 0% | Jun 2026 |
|
| Mercer Global Advisors | 50.00 | $900.000000 | 100% | Jun 2026 |
|
| Fortitude Family Office | 40.00 | $720.000000 | 0% | Jun 2026 |
|
| Quarry | 29.00 | $522.000000 | 100% | Jun 2026 |
|
| Advisor Group Holdings | 26.00 | $468.000000 | 0% | Jun 2026 |
|
| Caitong International Asset Management | 21.00 | $378.000000 | 425% | Jun 2026 |
|
| National Bank Of Canada /fi/ | 3.00 | $54.000000 | 100% | Jun 2026 |
|
Who sold out of Crescent Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Deep Track Capital | Mar 2026 | 454k | $8.3M |
| Alyeska Investment Group | Mar 2026 | 264k | $4.8M |
| Goldman Sachs Group | Mar 2026 | 229k | $4.2M |
| Susquehanna International | Mar 2026 | 214k | $3.9M |
| Hudson Bay Capital Management | Mar 2026 | 89k | $1.6M |
| Lighthouse Investment Partners | Mar 2026 | 25k | $459k |
| Renaissance Technologies | Mar 2026 | 24k | $446k |
| Brevan Howard Capital Management | Mar 2026 | 20k | $359k |
| OMERS Administration Corporation | Mar 2026 | 18k | $327k |
| Algert Coldiron Investors | Mar 2026 | 14k | $254k |
| Verdad Advisers | Mar 2026 | 13k | $234k |
| Cannon Global Investment Management | Mar 2026 | 10k | $187k |